Zobrazeno 1 - 6
of 6
pro vyhledávání: '"June Kuang"'
Autor:
Zhijun Tan, Vivekh Ehamparanathan, Tingwei Ren, Peifeng Tang, Laurel Hoffman, June Kuang, Peiran Liu, Chao Huang, Cheng Du, Li Tao, Letha Chemmalil, Angela Lewandowski, Sanchayita Ghose, Zheng Jian Li, Shijie Liu
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s
Externí odkaz:
https://doaj.org/article/18ea0b2eb9fc414ebf9fd1ddbcf039cb
Autor:
Julia Ding, Nesredin Mussa, June Kuang, Yuanqi Tao, Letha Chemmalil, Zheng Jian Li, Yuanli Song
Publikováno v:
Analytical and Bioanalytical Chemistry. 413:2113-2123
Isomerization of aspartic acid (Asp) in therapeutic proteins could lead to safety and efficacy concerns. Thus, accurate quantitation of various Asp isomerization along with kinetic understanding of the variant formations is needed to ensure optimal p
Autor:
Ryan, Knihtila, Letha, Chemmalil, Pranoti, Sawant, Sohil, Bhavsar, June, Kuang, Chun, Shao, Jennifer, Atsma, Zhengjian, Li, Julia, Ding
Publikováno v:
Journal of Chromatography B. 1212:123502
Monoclonal antibodies (mAbs) are complex glycoproteins that are developed for treatment of various therapeutic indications such as cancer and autoimmune diseases. MAbs are glycosylated at conserved asparagine residues (N-X-S/T) of the Fc region at am
Autor:
Ryan Knihtila, Xin Zhang, Dhanuka P. Wasalathanthri, Letha Chemmalil, Sohil Bhavsar, Jay A. A. West, Jianlin Xu, Kyle P. McHugh, Neha Puri, June Kuang, Qin He, Chun Shao, Zheng Jian Li, Matthew S. Rehmann, Michael Borys, Tanushree Prabhakar, Julia Ding, Robin Barbour
Publikováno v:
Biotechnology and bioengineeringREFERENCES. 118(9)
The biopharmaceutical industry is transitioning from currently deployed batch-mode bioprocessing to a highly efficient and agile next-generation bioprocessing with the adaptation of continuous bioprocessing, which reduces capital investment and opera
Autor:
Letha Chemmalil, Chun Shao, Sohil Bhavsar, June Kuang, Tanushree Prabhakar, Neha Puri, Jianlin Xu, Jay A. A. West, Matthew S. Rehmann, Michael Borys, Julia Ding, Zheng Jian Li, Qin He, Xin Zhang, Kyle P. McHugh, Ryan Knihtila, Dhanuka Wasalthanthri, Robin Barbour
The biopharmaceutical industry is transitioning from currently deployed batch-mode bioprocessing to a highly efficient and agile next generation bioprocessing with the adaptation of continuous bioprocessing, which reduces the capital investment and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c81bb14c632203892cb791de41e2d573
https://doi.org/10.22541/au.160977291.13543398/v1
https://doi.org/10.22541/au.160977291.13543398/v1
Autor:
Zheng Jian Li, Peiran Liu, Peifeng Tang, Zhijun Tan, June Kuang, Shijie Liu, Letha Chemmalil, Angela Lewandowski, Laurel Hoffman, Li Tao, Sanchayita Ghose, Chao Huang, Vivekh Ehamparanathan, Cheng Du, Tingwei Ren
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug’s